Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A Review.

Das S, Rousseau R, Adamson PC, Lo AW.

JAMA Oncol. 2018 Jun 2. doi: 10.1001/jamaoncol.2018.1739. [Epub ahead of print]

PMID:
29860493
2.

Treating chlamydial infections in pregnancy and preventing adverse birth outcomes.

Adamson PC, Klausner JD.

Lancet Infect Dis. 2018 Apr;18(4):368-369. doi: 10.1016/S1473-3099(18)30049-5. Epub 2018 Jan 19. No abstract available.

PMID:
29371068
3.

A systems-based assessment of the PrePex device adverse events active surveillance system in Zimbabwe.

Adamson PC, Tafuma TA, Davis SM, Xaba S, Herman-Roloff A.

PLoS One. 2017 Dec 22;12(12):e0190055. doi: 10.1371/journal.pone.0190055. eCollection 2017.

4.

Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.

Rau RE, Dreyer Z, Choi MR, Liang W, Skowronski R, Allamneni KP, Devidas M, Raetz EA, Adamson PC, Blaney SM, Loh ML, Hunger SP.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26873. Epub 2017 Nov 1.

5.

Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, Whitehead B, Jacobs B, Siegel DM, Keen R, Hsiao E, Pignolo RJ.

Bone. 2018 Apr;109:276-280. doi: 10.1016/j.bone.2017.07.019. Epub 2017 Jul 20.

PMID:
28736245
6.

Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R.

Haematologica. 2017 Sep;102(9):e340-e343. doi: 10.3324/haematol.2017.168815. Epub 2017 Jun 22. No abstract available.

7.

Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force.

Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E; Children's Oncology Group Chemotherapy Standardization Task Force.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26636. Epub 2017 May 16.

PMID:
28509433
8.

Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.

Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC, Seibel NL, Parsons DW, Cho YJ, Janeway K; Pediatric MATCH Target and Agent Prioritization Committee.

J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw274.

9.

Challenges in drug development for children.

Adamson PC.

Clin Adv Hematol Oncol. 2017 Jan;15(1):26-29. No abstract available.

PMID:
28212366
10.

Second monotherapy in childhood absence epilepsy.

Cnaan A, Shinnar S, Arya R, Adamson PC, Clark PO, Dlugos D, Hirtz DG, Masur D, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2017 Jan 10;88(2):182-190. doi: 10.1212/WNL.0000000000003480. Epub 2016 Dec 16.

11.

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

Weber JS, Levit LA, Adamson PC, Bruinooge SS, Burris HA 3rd, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM.

J Clin Oncol. 2017 Jan 10;35(2):139-140. Epub 2016 Nov 28. No abstract available.

12.

CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!

Cook-Sather SD, Adamson PC, Li J, Hakonarson H.

Anesthesiology. 2016 Dec;125(6):1085-1087. No abstract available.

13.

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, Ladanyi M, Meltzer P, Bult CJ, Adamson PC, Lupo PJ, Mody R, DuBois SG, Parsons DW, Khanna C, Lau C, Hawkins DS, Randall RL, Smith M, Sorensen PH, Plon SE, Skapek SX, Lessnick S, Gorlick R, Reed DR.

Cancer Genet. 2016 May;209(5):182-94. doi: 10.1016/j.cancergen.2016.03.004. Epub 2016 Apr 5. Review.

14.

The 2016 ASPHO Distinguished Career Award Goes to David G. Poplack, MD.

Blaney SM, Adamson PC, Wechsler DS.

Pediatr Blood Cancer. 2016 Jun;63 Suppl 1:S5-6. doi: 10.1002/pbc.25978. No abstract available.

PMID:
27077669
15.

Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.

Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R.

J Clin Oncol. 2016 May 1;34(13):1537-43. doi: 10.1200/JCO.2015.65.5860. Epub 2016 Feb 16.

16.

When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.

Adamson PC, Park JR, Pearson AD.

Pediatr Blood Cancer. 2016 Jun;63(6):962-3. doi: 10.1002/pbc.25891. Epub 2016 Jan 6. No abstract available.

PMID:
26740172
17.

Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group.

Li Y, Hall M, Fisher BT, Seif AE, Huang YS, Bagatell R, Getz KD, Alonzo TA, Gerbing RB, Sung L, Adamson PC, Gamis A, Aplenc R.

PLoS One. 2015 Nov 25;10(11):e0143480. doi: 10.1371/journal.pone.0143480. eCollection 2015.

18.

Acceptability and Accuracy of Cervical Cancer Screening Using a Self-Collected Tampon for HPV Messenger-RNA Testing among HIV-Infected Women in South Africa.

Adamson PC, Huchko MJ, Moss AM, Kinkel HF, Medina-Marino A.

PLoS One. 2015 Sep 2;10(9):e0137299. doi: 10.1371/journal.pone.0137299. eCollection 2015.

19.

Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial.

Shinnar S, Cnaan A, Hu F, Clark P, Dlugos D, Hirtz DG, Masur D, Mizrahi EM, Moshé SL, Glauser TA; Childhood Absence Epilepsy Study Group.

Neurology. 2015 Sep 29;85(13):1108-14. doi: 10.1212/WNL.0000000000001971. Epub 2015 Aug 26.

20.

Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.

Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R.

Pediatr Blood Cancer. 2015 Oct;62(10):1775-81. doi: 10.1002/pbc.25569. Epub 2015 May 6.

21.

Improving the outcome for children with cancer: Development of targeted new agents.

Adamson PC.

CA Cancer J Clin. 2015 May-Jun;65(3):212-20. doi: 10.3322/caac.21273. Epub 2015 Mar 9. Review.

22.

Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.

Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Zeng H, Whitlock JA, Adamson PC, Hunger SP, Carroll WL.

Pediatr Blood Cancer. 2015 Jul;62(7):1171-5. doi: 10.1002/pbc.25454. Epub 2015 Mar 2.

23.

The impact of chemotherapy shortages on COG and local clinical trials: a report from the Children's Oncology Group.

G Salazar E, Bernhardt MB, Li Y, Aplenc R, Adamson PC.

Pediatr Blood Cancer. 2015 Jun;62(6):940-4. doi: 10.1002/pbc.25445. Epub 2015 Feb 19.

24.

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA 4th, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM.

J Clin Oncol. 2015 Jan 20;33(3):278-84. doi: 10.1200/JCO.2014.58.2635. Epub 2014 Dec 15. No abstract available.

25.

Reply to N.-K.V. Cheung et al.

Matthay KK, London WB, Maris J, Adamson PC, Park JR.

J Clin Oncol. 2014 Dec 20;32(36):4174-5. doi: 10.1200/JCO.2014.58.7006. Epub 2014 Nov 17. No abstract available.

26.

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

J Clin Oncol. 2014 Dec 1;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. Epub 2014 Oct 27.

27.

A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma.

Moorthy GS, Norris RE, Adamson PC, Fox E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Nov 15;971:30-4. doi: 10.1016/j.jchromb.2014.09.005. Epub 2014 Sep 16.

28.

Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.

Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B.

Pediatr Blood Cancer. 2015 Jan;62(1):45-51. doi: 10.1002/pbc.25229. Epub 2014 Sep 24.

29.

AACR Cancer Progress Report 2014.

Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ.

Clin Cancer Res. 2014 Oct 1;20(19 Suppl):S1-S112. doi: 10.1158/1078-0432.CCR-14-2123. Epub 2014 Sep 16. No abstract available.

30.

Drug discovery in paediatric oncology: roadblocks to progress.

Adamson PC, Houghton PJ, Perilongo G, Pritchard-Jones K.

Nat Rev Clin Oncol. 2014 Dec;11(12):732-9. doi: 10.1038/nrclinonc.2014.149. Epub 2014 Sep 16. Review.

31.

The Children's Oncology Group Childhood Cancer Research Network (CCRN): case catchment in the United States.

Musselman JR, Spector LG, Krailo MD, Reaman GH, Linabery AM, Poynter JN, Stork SK, Adamson PC, Ross JA.

Cancer. 2014 Oct 1;120(19):3007-15. doi: 10.1002/cncr.28813. Epub 2014 May 29.

32.

Too few medicines for children with cancer--reply.

Adamson PC.

JAMA Pediatr. 2014 Jun;168(6):583-4. doi: 10.1001/jamapediatrics.2014.18. No abstract available.

PMID:
24886802
33.

Declining childhood and adolescent cancer mortality.

Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL.

Cancer. 2014 Aug 15;120(16):2497-506. doi: 10.1002/cncr.28748. Epub 2014 May 22.

34.

Toward a drug development path that targets metastatic progression in osteosarcoma.

Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M.

Clin Cancer Res. 2014 Aug 15;20(16):4200-9. doi: 10.1158/1078-0432.CCR-13-2574. Epub 2014 May 6.

35.

Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).

Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM.

Pediatr Blood Cancer. 2014 Jun;61(6):990-6. doi: 10.1002/pbc.24900. Epub 2013 Dec 18.

36.

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.

Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S.

Pediatr Blood Cancer. 2014 May;61(5):833-9. doi: 10.1002/pbc.24874. Epub 2013 Nov 19.

37.

It seemed like a good idea at the time.

Adamson PC.

Pediatr Blood Cancer. 2014 Feb;61(2):187-8. doi: 10.1002/pbc.24669. Epub 2013 Sep 30. No abstract available.

PMID:
24115462
38.

Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.

Norris RE, Adamson PC, Nguyen VT, Fox E.

Pediatr Blood Cancer. 2014 Jan;61(1):145-50. doi: 10.1002/pbc.24697. Epub 2013 Sep 4.

39.

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.

Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM.

Pediatr Blood Cancer. 2014 Mar;61(3):452-6. doi: 10.1002/pbc.24605. Epub 2013 Aug 17.

40.

Unintended consequences of regulatory initiatives in childhood cancer drug development.

Adamson PC.

JAMA Pediatr. 2013 Oct;167(10):886-7. doi: 10.1001/jamapediatrics.2013.2488. No abstract available.

PMID:
23938865
41.

Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcome.

Dlugos D, Shinnar S, Cnaan A, Hu F, Moshé S, Mizrahi E, Masur D, Sogawa Y, Le Pichon JB, Levine C, Hirtz D, Clark P, Adamson PC, Glauser T; Childhood Absence Epilepsy Study Team.

Neurology. 2013 Jul 9;81(2):150-6. doi: 10.1212/WNL.0b013e31829a3373. Epub 2013 May 29.

42.

Evaluation of the retinoids with cisplatin and vincristine in xenograft models of neuroblastoma.

Norris RE, Nguyen VT, Adamson PC.

J Pediatr Hematol Oncol. 2014 Jan;36(1):e23-7. doi: 10.1097/MPH.0b013e3182915d4a.

43.

Developing drugs for pediatric malignancies.

Adamson PC.

Clin Adv Hematol Oncol. 2013 Apr;11(4):227-9. No abstract available.

PMID:
23604239
44.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM.

Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.

45.

Imaging in childhood cancer: a Society for Pediatric Radiology and Children's Oncology Group Joint Task Force report.

Weiser DA, Kaste SC, Siegel MJ, Adamson PC.

Pediatr Blood Cancer. 2013 Aug;60(8):1253-60. doi: 10.1002/pbc.24533. Epub 2013 Apr 9. Review.

46.

New drugs for children and adolescents with cancer: the need for novel development pathways.

Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P, Adamson PC.

Lancet Oncol. 2013 Mar;14(3):e117-24. doi: 10.1016/S1470-2045(13)70013-5. Epub 2013 Feb 20.

PMID:
23434337
47.

The Children's Oncology Group's 2013 five year blueprint for research.

Adamson PC.

Pediatr Blood Cancer. 2013 Jun;60(6):955-6. doi: 10.1002/pbc.24399. Epub 2012 Dec 19. No abstract available.

48.

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC; Childhood Absence Epilepsy Study Team.

Epilepsia. 2013 Jan;54(1):141-55. doi: 10.1111/epi.12028. Epub 2012 Nov 21.

49.

Recommendations for the return of research results to study participants and guardians: a report from the Children's Oncology Group.

Fernandez CV, Ruccione K, Wells RJ, Long JB, Pelletier W, Hooke MC, Pentz RD, Noll RB, Baker JN, O'Leary M, Reaman G, Adamson PC, Joffe S; COG Return of Results Task Force.

J Clin Oncol. 2012 Dec 20;30(36):4573-9. doi: 10.1200/JCO.2012.45.2086. Epub 2012 Oct 29.

50.

Challenges and opportunities in childhood cancer drug development.

Norris RE, Adamson PC.

Nat Rev Cancer. 2012 Nov;12(11):776-82. doi: 10.1038/nrc3370. Epub 2012 Oct 11. Review.

PMID:
23051845

Supplemental Content

Loading ...
Support Center